Written Comments. Written comments regarding the proposed payment rates may be submitted in lieu of, or in addition to, oral testimony until 5:00 p.m. the day of the hearing. Written comments may be sent by U.S. mail to the Texas Health and Human Services Commission, Attention: Rate Analysis, Mail Code H-400, Brown-Healy Building, 4900 North Lamar Blvd, Austin, Texas 78751.

Persons with disabilities who wish to attend the hearing and require auxiliary aids or services should contact Rate Analysis at (512) 730-7401 at least 72 hours before the hearing so appropriate arrangements can be made.

TRD-201902102
Karen Ray
Chief Counsel
Texas Health and Human Services Commission
Filed: July 3, 2019

Public Notice: Revised Texas State Plan for Medical Assistance Amendment

In the June 7, 2019, issue of the Texas Register, (44 TexReg 2889), the Texas Health and Human Services Commission (HHSC) published notice of its intent to submit transmittal number 19-0019 to the Texas State Plan for Medical Assistance under Title XIX of the Social Security Act.

The purpose of the amendment is to remove recent revisions to the inflation projection methodology for the Intermediate Care Facilities for Individuals with an Intellectual Disability (ICF/IID) and to the nursing wage inflation methodology, which affect ICF/IID programs. The proposed amendment reflects HHSC’s decision not to use the revised methodology for the nurse inflator calculations at this time.

The proposed amendment is estimated to have no fiscal impact.

The effective date has changed from June 1, 2019, to July 1, 2019.

For questions concerning this revised notice, interested parties may contact Courtney Pool, State Plan Program Coordinator, by mail at the Texas Health and Human Services Commission, P.O. Box 13247, Mail Code H-600, Austin, Texas 78711; by telephone at (512) 424-6889; by facsimile at (512) 730-7472; or by e-mail at Medicaid_Chip_SPA_Inquiries@hhsc.state.tx.us. Copies of the proposed amendment will be available for review at the local county offices of the Texas Health and Human Services Commission.

TRD-201902211
Karen Ray
Chief Counsel
Texas Health and Human Services Commission
Filed: June 25, 2019

Department of State Health Services

Order Permanently Placing Beta-hydroxythiofentany1 in Schedule I

The Administrator of the Drug Enforcement Administration issued a final rule permanently placing beta-hydroxythiofentany1 including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers in
This final order was published in the Federal Register, Volume 84, Number 89, pages 20023-20027.

This scheduling action was taken pursuant to the following:
1. beta-hydroxythiofentanyl has a high potential for abuse;
2. beta-hydroxythiofentanyl has no currently accepted medical use in treatment in the United States; and,
3. There is a lack of accepted safety for use of beta-hydroxythiofentanyl under medical supervision.

Pursuant to Section 481 (34(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Health and Safety Code, Chapter 481, at least thirty-one days have expired since notice of the above referenced actions were published in the Federal Register. In the capacity as Commissioner of the Texas Department of State Health Services, John Hellerstedt, M.D., does hereby order that the substance beta-hydroxythiofentanyl be permanently placed into schedule 1.

Schedule 1 Opiates

The following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, if the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:

(1) Acetyl alpha methylfenanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidiny]-N-phenylacetamid);
(2) AH-7921 (3,4-dichloro-N-[3(dimethylamino)cyclohexymethyl]benzamide);
(3) Acetyl fentanyl (N-(1-phenethyl)piperidin-4-yl)-N-phenylacetamide);
(4) Acetyl fentanyl [N-(1-phenethyl)piperidin-4-yl]-N-phenylacrylamid) (Other names: acetyl fentanyl); (5) AH-7921 (3,4-dichloro-N-[3(dimethylamino)cyclohexymethyl]benzamide);
(6) Alkyjprodine;
(7) Algacecyclomethanol (except levo-alphabetomethanol, also known as levo-alpha-acetylmethanol, levomethadyl acetate, or LAAM);
(8) Alpha-methylfentanyl or any other derivative of fentanyl;
(9) Alpha-methylthiofenyln (N-[1-methyl-2-(2-thienyl)ethyl]-4-piperidinyl)-N-phenyl-propanamide;
(10) Benzolodirine;
(11) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenyl-propanamide);
(12) Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenyl-propanamide);
* (13) betahydroxythiofentanyl (N-[1-(2-hydroxy-2-thiophen-2-yl)ethyl]-4-piperidinyl)-N-phenylpropanamide, also known as N-[1-(2-hydroxy-2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide;
(14) Betaprodine;
(15) Butylfenyl fentanyl (N-[1-phenethylpiperidin-4-yl]-N-phenylbutanamide);
(16) Clonazolane;
(17) Diapromide;
(18) Diethylihambutene;
(19) Difenoxin;
(20) Dimezoxol;
(21) Dimezothiobutene;
(22) Dio MPH-ethyl fentanyl; (23) Dipanone;
(24) Ethylmethylthiobutene;
(25) Etozolazene;
(26) Etosoridine;
(27) 4-Fluorosiloxyl fentanyl (N-4-fluorophenyl]-N-(1-phenethyl)piperidin-4-yl)isobutyramide) (Other names: paro-fluorosiloxyl fentanyl); (28) Furanyl fentanyl (N-[1-phenethylpiperidin-4-yl]-N-phenylfuram-2-carboxamide);
(29) Furathidine;
(30) Hydroxycytoxidone;
(31) Ketobemidone;
(32) Levophenacylmonorphan;
(33) Meproside;
(34) 3-methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidinyl]-N-phenylpropanamide), its optical and geometric isomers;
(35) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
(36) Moramide;
(37) Morpiperidine;
(38) MPPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
(39) MT-45 (1-cyclohexyl-4-(1,2-diphenoylethyipiperazine);
(40) Norcamphetamine;
(41) Norlevorphanol;
(42) Normethadone;
(43) Normipanone;
(44) Oxfenitil (N-[2-fluorophenyl]-2-methoxy-N-(1-phenethyl)piperidin-4-yl)acetamide);
(45) Para-fluorosiloxyl fentanyl (N-4-fluorophenyl]-N-[1-(2-phenethyl)-4-piperidinyl]-propanamide);
(46) PEAP (1-(2-phenethyl)-4-phenyl-4-acetoxyppiperidin);
(47) Phenadoxone;
(48) Phenampronide;
(49) Phenacyclidine;
(50) Phenomorphine;
(51) Phenoperidine;
(52) Piritrimadine;
(53) Procopantine;
(54) Properidine;
(55) Propiram;

IN ADDITION  July 12, 2019  44 TexReg 3571
Texas Department of Insurance

Texas Lottery Commission

Scratch Ticket Game Number 2124 "Winning 7s"

1.0 Name and Style of Scratch Ticket Game
A. The name of Scratch Ticket Game No. 2124 is "WINNING 7s". The play style is "other".

1.1 Price of Scratch Ticket Game
A. The price for Scratch Ticket Game No. 2124 shall be $1.00 per Scratch Ticket.

1.2 Definitions in Scratch Ticket Game No. 2124
A. Display Printing - That area of the Scratch Ticket outside of the area where the overprint and Play Symbols appear.
B. Latex Overprint - The removable scratch-off covering over the Play Symbols on the front of the Scratch Ticket.
C. Play Symbol - The printed data under the latex on the front of the Scratch Ticket that is used to determine eligibility for a prize. Each Play Symbol is printed in Symbol font in black ink in positive except for dual-image games. The possible black Play Symbols are:
1, 2, 3, 4, 5, 6, 7, 8, 9, 7 SYMBOL, $1.00, $2.00, $3.00, $4.00, $5.00, $6.00, $10.00, $20.00, $50.00 and $500.
D. Play Symbol Caption - The printed material appearing below each Play Symbol which explains the Play Symbol. One caption appears under each Play Symbol and is printed in caption font in black ink in positive. The Play Symbol Caption which corresponds with and verifies each Play Symbol is as follows: